These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12654737)

  • 21. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination antibody treatment controls HIV infection in phase 1 trial.
    Harper KN
    AIDS; 2019 Mar; 33(3):N3-N4. PubMed ID: 30585848
    [No Abstract]   [Full Text] [Related]  

  • 24. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
    Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
    AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for passive immunity to prevent HIV infection.
    Morris L; Mkhize NN
    PLoS Med; 2017 Nov; 14(11):e1002436. PubMed ID: 29136030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
    Dimitrov A
    Curr Opin Investig Drugs; 2007 Aug; 8(8):653-61. PubMed ID: 17668367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human xenograft models for virus infection.
    Mosier DE
    Virology; 2000 Jun; 271(2):215-9. PubMed ID: 10860873
    [No Abstract]   [Full Text] [Related]  

  • 28. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies.
    Alving CR; Beck Z; Karasavva N; Matyas GR; Rao M
    Mol Membr Biol; 2006; 23(6):453-65. PubMed ID: 17127618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of predictive markers of HIV disease progression in vaccine trials.
    Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
    Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy.
    Gros L; Pelegrin M; Plays M; Piechaczyk M
    J Virol; 2006 Oct; 80(20):10191-200. PubMed ID: 17005696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [One antibody preparation is not the other: the role of passive immunotherapy in the treatment of HIV infections].
    Laane HM
    Ned Tijdschr Geneeskd; 1995 Apr; 139(16):850-1. PubMed ID: 7731480
    [No Abstract]   [Full Text] [Related]  

  • 34. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
    Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L
    Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
    Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
    Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV vaccines under study.
    Ravanfar P; Mendoza N; Satyaprakash A; Jordan BI
    Dermatol Ther; 2009; 22(2):158-67. PubMed ID: 19335727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from failure--preparing for future HIV-1 vaccine efficacy trials.
    Graham BS; Mascola JR
    J Infect Dis; 2005 Mar; 191(5):647-9. PubMed ID: 15688276
    [No Abstract]   [Full Text] [Related]  

  • 38. New treatment reduces bacterial infections in HIV-positive children.
    Neonatal Netw; 1991 Apr; 9(7):58-9. PubMed ID: 2062289
    [No Abstract]   [Full Text] [Related]  

  • 39. A recombinant human monoclonal anti-R7V antibody as a potential therapy for HIV infected patients in failure of HAART.
    Haslin C; Lévêque M; Ozil A; Cérutti P; Chardès T; Chermann JC; Duonor-Cérutti M
    Hum Antibodies; 2007; 16(3-4):73-85. PubMed ID: 18334743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.